Investor FAQs

Show All
Where is Aldeyra Therapeutics’ corporate headquarters?
Our corporate headquarters are located at 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
When was Aldeyra Therapeutics founded?
The Company was founded in 2004.
Where is the Company incorporated?
The Company is incorporated in Delaware.
When did Aldeyra Therapeutics go public? What was the price?
Aldeyra Therapeutics common stock began trading on The Nasdaq Capital Market on May 2, 2014.
The initial public offering price was $8.00 per share.
What is Aldeyra Therapeutics’ fiscal year?
The Company’s fiscal year ends December 31st.
Where is Aldeyra Therapeutics’ stock traded?
Our common stock is listed on The Nasdaq Capital Market under the symbol “ALDX.”
Who is Aldeyra Therapeutics’ transfer agent?
The transfer agent and registrar for the common stock of Aldeyra Therapeutics is:

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
718.921.8300
How do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate?
To change the address on your shareholder account you must send both your old and new addresses to our transfer agent, American Stock Transfer & Trust Company, LLC.

To transfer stock or replace a lost stock certificate, contact our transfer agent, American Stock Transfer & Trust Company, LLC.
Who is Company's auditor?
The auditor for Aldeyra Therapeutics is BDO USA, LLP located in Boston, MA.
Who is the Company’s legal counsel?
Legal counsel for Aldeyra Therapeutics is Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP located in Boston, MA.
Where can I find out more about Aldeyra Therapeutics?
To find out more about Aldeyra Therapeutics visit our website at www.aldeyra.com.
Where can I get the latest corporate news releases and financial reports?
Aldeyra Therapeutics press release archive can be viewed under the “Press Releases” section of the “Investors & Media” page located at our website: www.aldeyra.com.
How can I view documents Aldeyra Therapeutics has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?
Aldeyra Therapeutics’ SEC Filings can be found on www.sec.gov and are also available under the “SEC Filings” section of the “Investors & Media” page located at our website www.aldeyra.com.
Who makes up the Aldeyra Therapeutics Executive Management team and Board of Directors?
For a list of the Executive Management team and Board of Directors please visit the “Leadership Team & Board of Directors” page of our website.
Whom should I contact regarding investor inquiries?
For investor inquiries please contact:

Scott Solomon
Sharon Merrill Associates
Senior Vice President
EMAIL: ALDX@investorrelations.com
PHONE: 857-383-2409
Whom should I contact regarding media inquiries?
For media inquiries please contact:

Scott Solomon
Sharon Merrill Associates
Senior Vice President
EMAIL: ALDX@investorrelations.com
PHONE: 857-383-2409

Safe Harbor Disclosure

This video content contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K. Any forward-looking statements that are made in the video content are based on assumptions as of the original date of the creation of such video, and Aldeyra undertakes no obligation to update these statements as a result of new information or future events.

Continue to video